Thursday 28 August 2014

Catheters Market Will Reach USD 33.3 Billion Globally in 2017


Global catheters market was worth USD 20.4 billion in 2011 and is further expected to reach USD 33.3 billion in 2017, growing at a CAGR of 8.5% from 2011 to 2017. The cardiovascular catheter was the largest market segment at USD 8.3 billion in 2011. Globally, North America was the largest regional market with 44.3% share in 2011; however European region is expected to take the lead position post 2016.

Browse the full report at Catheters Market http://www.transparencymarketresearch.com/catheters-market.html

The global catheters market is expected to reach USD 22.6 billion in 2012. Aging population in both developed and emerging markets, patient's choice for minimally invasive procedures, and product innovations are key growth drivers for the market. The catheter devices market is segmented into cardiovascular, specialty, urological, neurovascular, and intravenous catheters. Among all types of catheters, cardiovascular catheters account for about 40.9% of the global catheter market.

This report analyzes the worldwide market for catheters for the period of 2010 to 2017. The in-depth research and high level analysis will allow catheters product manufacturers, service providers, marketing companies, research and development agencies to make informed decisions about catheters manufacturing, marketing, growth strategies and gaining competitive advantage.


Geographies Covered
North America
Europe
Asia-Pacific
China
Rest of the World (RoW)


Catheters Segments Covered
Cardiovascular
Neurovascular
Intravenous
Urological
Specialty


Reasons to purchase this report

This research is specially designed to estimate and analyze the demand and performance of the global and China catheters market. The report covers all the major segments of catheters market and provides in-depth analysis, market revenue, and trend analysis by segments and statistically refined forecast for the segments covered. The report also provides:

Definition, estimates & forecast for the global and China catheters market from 2010 to 2017

Market forces driving and restraining the growth of the market
Up-to-date analysis of the latest trends in the industry
Leading industry opinion keeps you abreast of latest news and trends
Forward-looking outlook on a category, market or issue affecting the industry
Make more informed business decisions from insightful and in-depth analysis of the market performance

About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Wednesday 27 August 2014

Smoking Cessation and Nicotine De-addiction Products Market Trends 2013 - 2019


The global smoking cessation and nicotine de-addiction productsmarket was valued at USD 5.1 billion in 2012 and is expected to grow at a CAGR of 18.7% from 2013 to 2019, to reach an estimated value of USD 16.02billion in 2019.

Smoking cessation is a process of discontinuing smoking achieved by the use of medication. It may also be coupled with assistance of healthcare professionals, counselling and psychotherapy. The demand for smoking cessation products is high and is continuously rising as it caters to the needs of people addicted to nicotine and rising healthcare awareness amongst the smokers. The global smoking cessation and nicotine de-addiction products market is segmented on the basis of product types available in the market. These include nicotine replacement therapy (NRT) products, drug therapy and e-cigarettes. This market is sustained by large number of people wanting to quit smoking.

Browse Global Smoking Cessation and Nicotine De-addiction Products Market Report with Full TOC at http://www.transparencymarketresearch.com/smoking-cessation-nicotine-de-addiction-products.html

NRT products for smoking cessation include nicotine containing gums, patches, lozenges, sublingual tablets, inhalers and mouth sprays. The market for NRT products is dominated by the revenue of nicotine gums, patches and lozenges. Nicotine gums are one of the most widely used NRT products, and the market for these was valued at USD 995.5 million in 2012. The nicotine patches and lozenges market is driven by its ease of use and non-prescription sale. Nicotine sprays and inhalers on the other hand are less preferred due to their high cost and less popularity. However, increased promotional activities and effective distribution is expected to boost their market growth in the near future. The major players in the NRT products market include Johnson and Johnson, GSK, Cipla and Novartis.

Smoking cessation drug therapy market is expected to witness a decline in revenue across the globe, by the end of the forecast period due to patent expiration of the key revenue generating drugs Zyban (bupropion) in 2013 and Chantix/Champix (varenicline) in 2018 (which will impede market growth toa lower extent). The loss of patent and marketing exclusivity will lead to a drastic reduction in revenue and in turn provide an opportunity to generic manufacturers to launch their own versions of these brands. The leading players in the drug therapy market are GSK and Pfizer.

The e-cigarettes segment is expected to witness the fastest growth, and thus, will boost growth of the global smoking cessation and nicotine de-addiction products market during the forecast period. E-cigarettes have proved to be a better alternative to cigarettes whose smoke contains various harmful gases and cause dreadful diseases such as cancer. With the exceptional growth and popularity among the younger population, the market has posed a challenge to other smoking cessation products as well as to the tobacco cigarette business. The global e-cigarettes market was worth USD 1,662.5 million in 2012. Lorillard, NJOY and VMR products LLC are some of the major players in the e-cigarettes market.


Geographically, North America dominates the global smoking cessation and nicotine de-addiction products market. The North American market for smoking cessation products was valued at USD 1,958.8 million in the year 2012. An increase in cigarette costs is expected to reduce smoking rates significantly, especially in adolescents. According to the CDC, a 10% rise in cigarettes cost can cut around 4% of young adults craving cigarette consumption. The European market held the second largest share worldwide, in 2012. WHO reports that European countries have widely adopted bans on tobacco advertising, promotion on national/international television and radio, billboards and outdoor advertising, local magazines and newspapers. However, some countries in Europe still lack in implementing measures of the WHO Framework Convention on Tobacco Control (FCTC).

Raising taxes to increase the cost of cigarettes can reduce tobacco use, cut smoking rates, and ultimately save lives. Smoking prevalence has been varying across the globe with many developing countries witnessing rapid increase in the prevalence rate, which will create huge health problems for the future if left unchecked. Demand for lifestyle drugs in emerging countries is witnessing rapid growth due to factors including growing health awareness, increase in population, and development of public healthcare systems, among others. This is driving people towards quitting smoking by adopting smoking cessation products. A study in the Eastern Mediterranean Health Journal, published in 2012, reported that nicotine containing medications are not available in one third of the developing countries, which include the Middle East and Africa. Moreover, accessibility of non-nicotine containing medications such as bupropion and varenicline is also extremely low. Increased attention and resources are needed to address lack of smoking cessation services as well as access to nicotine containing medications in these regions.


The global smoking cessation and nicotine de-addiction products market is segmented as follows

Smoking Cessation and Nicotine De-Addiction Products Market, by Product Type


Nicotine Replacement Therapy Products
Nicotine Gums
Nicotine Transdermal Patches
Nicotine Lozenges
Nicotine Sprays
Nicotine Inhalers
Nicotine Sublingual Tablets
Drug Therapy
Zyban (bupropion)
Chantix/Champix (varenicline)
E-cigarettes

Smoking Cessation and Nicotine De-Addiction Products Market, by Geography
North America
Europe
Asia-Pacific
Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Web: http://www.transparencymarketresearch.com/

Erectile Dysfunction Drugs Market Analysis 2013 - 2019


The global erectile dysfunction drugs market was valued at USD 4.3 billion in 2012 and is expected to decline at a CAGR of (4.5%) from 2013 to 2019, to reach an estimated value of USD 3.4 billion in 2019.

Browse the full report with complete TOC at Erectile Dysfunction Drugs Market http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html

Erectile dysfunction is the inability to attain or maintain penile erection in men, sufficient for successful sexual intercourse. Erectile dysfunction is a common medical disorder primarily affecting men older than 40 years of age. In addition, other than the typical causes of erectile dysfunction, such as diabetes and hypertension, a number of common lifestyle related factors are also associated with development of the condition. These include obesity, excessive alcohol consumption, smoking, use of recreational drugs, and poor physical and psychological health. Commonly, oral drugs belonging to the PDE 5 inhibitors class form the mainstay of erectile dysfunction treatment. Other treatment options include lifestyle modification, testosterone therapy, penile devices, injection therapies and psychotherapy.

The global market for erectile dysfunction drugs has been studied from the perspective of currently marketed branded drugs and pipeline drugs. Branded drugs include Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), MUSE (medicated urethral systems for erection), Mvix (mirodenafil) and Helleva (lodenafil). The drugs in the pipeline for erectile dysfunction treatment primarily consist of two major drugs, namely Vitaros (alprostadil) and Uprima (apomorphine) currently in later phases of clinical trials.

In 2012, Viagra (sildenafil citrate) accounted for the largest share (45%) by revenue of the total erectile dysfunction drugs market. However, due to the loss of the drug's patent exclusivity in Europe and other countries in 2013, the overall market revenue is expected to decline during the forecast period as international markets contribute considerably to the overall market revenue of the drug. In the U.S. market, Viagra will continue to maintain a major revenue share due to its extended patent exclusivity till 2020. The market for Cialis (tadalafil) accounted for the second largest share at USD 1,926.8 million, in 2012. However, it is expected to witness a decline in market revenue at a CAGR of (12.6%) from 2013 to 2019, owing to loss of patent exclusivity in 2017. In addition, the patent for Bayer's Levitra/Staxyn (vardenafil) is scheduled to expire in 2018 and is thus expected to contribute to the declining market revenue.


A few novel compounds are currently under investigation in both preclinical and clinical settings, for the treatment of impotency. These studies are majorly focused on medications with improved efficacy, shorter onset of action and fewer side effects as compared to the currently available treatments. Such pipeline drugs include Vitaros (alprostadil), Uprima (apomorphine) and Topiglan (alprostadil), amongst others.

Geographically, North America dominated the global market for erectile dysfunction drugs in terms of revenue generation and is expected to maintain its position throughout the forecast period. The extended patent exclusivity for Pfizer's Viagra (sildenafil citrate) in the U.S., till 2020, will be responsible for the leadership of the North American market. Europe was the second largest regional market for erectile dysfunction drugs in 2012, owing to the increased demand for ED drugs. Market growth will also be facilitated by the expected marketing approvals for a few promising drug candidates such as Stendra/Spedra (avanafil) and Zydena (udenafil) by mid 2014.


The global erectile dysfunction dugs market is dominated by few major players including Pfizer, Inc. Eli Lilly & Co., and Bayer AG. Post patent expiration of the major branded drugs and intense genericization of the market, the competition in this market is expected to be characterized by consolidation activities, partnerships, and intensive mergers and acquisitions. The other key players in the erectile dysfunction drugs market include Dong-A Pharmaceutical Co. Ltd., Vivus, Inc., Apricus Biosciences, Inc. and Meda Pharmaceuticals.


The global erectile dysfunction drugs market is segmented as follows:

Erectile Dysfunction Drugs Market, by Major Branded Products
Viagra
Cialis
Levitra/Staxyn
Stendra/Spedra
Zydena
MUSE
Mvix
Helleva

Erectile Dysfunction Drugs Market, Pipeline Analysis
Vitaros
Uprima
Others
Topiglan
Melanocortin Activators
Gene Therapy

Erectile Dysfunction Drugs Market, by Geography
North America
Europe
Asia-Pacific
Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Web: http://www.transparencymarketresearch.com/
Blog: http://www.tmrblog.com/



Tuesday 26 August 2014

Global Biological Drugs Market is Expected to Reach USD 287,139.7 Million in 2020


The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach an estimated value of USD 287,139.7 million in 2020.

Browse the full Biological Drugs Market Report at http://www.transparencymarketresearch.com/biological-drugs-market.html

The biological drugs market is witnessing a significant growth due to the increasing prevalence of chronic diseases and increase in the global geriatric population. Biological drugs are used in treatment and prevention of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders. Moreover, various government associations are also promoting the usage of biological drugs. Furthermore, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market.

On the other hand, high cost of biological drugs and patent expiry of blockbuster drugs impede the growth of the market. Moreover, the risk of adverse effects associated with biologic injectable drugs is also one of the key restraints of the market. As a result, biological drugs market is expected to grow a CAGR of about 10.1% during 2014-2020.


North America is the largest market for biological drugs. Increased use of biological drugs for the treatment of diseases such as cancer, diabetes and other chronic diseases are supporting the growth of the biological drugs market in the region. The American Center for Biological Medicine (ACBM) is one of the largest biological medicine clinics in the U.S.

Similarly, the European biological drugs market is growing rapidly due to increased usage of biological drugs for the treatment of various chronic diseases such as diabetes, cancer and inflammatory diseases.

In Asia, low manufacturing cost is attracting many biological manufactures to invest in Asian countries, supporting the growth of the biological drugs market. Moreover, Asian governments are also supporting growth of the biological drugs market by increased investment on biotech companies for construction of R&D and manufacturing facilities.


Novartis AG, Pfizer Inc., GlaxoSmithKline plc. and Merck & Co., Inc. are the some of the leading players in the global biological drugs market. Other major players of biological drugs market include Abbott Laboratories, Biogen Idec and Amgen Inc.

The global market of biological drugs is segmented as follows:


Biological Drugs Market, By Therapeutic Protein
Enbrel
Lantus
Neulasta
Avonex
NovoLog
Rebif
Humalog
Aranesp
Epogen
Levemir
Victoza
Betaseron
Neupogen
Eylea


Biological Drugs Market, By Monoclonal Antibody (mAb)
Humira
Remicade
Rituxan
Avastin
Herceptin
Lucentis

Biological Drugs Market, By Vaccine
Prenvar 13
Gardasil
Fluzone
Varivax
Cervarix

Biological Drugs Market, by Geography
North America
Europe
Asia
Rest of the World (RoW)


Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Ms. Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
Company Blog: http://www.tmrblog.com/


Sunday 24 August 2014

Medical Imaging Reagents Market Trends 2013 - 2019


The global medical imaging reagents market was valued at USD 10.3 billion in 2012 and is expected to grow at a CAGR of 8.8% from 2013 to 2019, to reach an estimated value of USD 18.5 billion in 2019.

Browse the full Medical Imaging Reagents Market Report at http://www.transparencymarketresearch.com/biologic-imaging-reagents-market.html

Medical imaging reagents are chemical compounds specially designed to enhance images produced through imaging systems. Medical imaging reagents allow clinicians and healthcare providers to determine whether a tumor is malignant or benign and enables to locate any metastatic cancerous sites in the body. The development of a medical imaging reagent involves synthesizing it to target a particular biological process, after which imaging systems are adjusted to neutralize the particular target. Medical imaging reagents are first studied via pre-clinical animal research before engaging in human clinical studies. The growth of the medical imaging reagents market can be attributed to the increasing demand for diagnostic and functional imaging technologies. In addition, companies in this industry are trying to stay abreast with technological innovations such as hybrid imaging modalities (e.g. SPECT + MR and PET + CT), which would alternatively boost the market growth of novel imaging reagents such as nuclear reagents and nanoparticles.

According to the Union for International Cancer Control (UICC), worldwide cancer cases are estimated to rise by almost 75% and reach approximately 25 million over the next two decades. Moreover, according to the American Cancer Society, it has been estimated that in 2014, approximately 1,665,540 new cases of cancer would be diagnosed and almost 585,720 deaths would occur due to cancer in the U.S. This increasing base of cancer patients would need advanced diagnostic imaging modalities such as photoacoustic imaging and PET+MRI as well as imaging reagents for better diagnosis, prevention and treatment of the disease, which would consequently increase the demand for medical imaging reagents.


The medical imaging reagents market has been primarily segmented by class, by technology and by applications. The medical imaging reagents class market further comprises contrast reagents, optical reagents and nuclear reagents. The contrast reagents market of the medical imaging reagents accounted for the largest market. However, among these categories, the nuclear reagents market is expected to foresee highest growth rate of over 14% from 2013 to 2019.

Moreover, medical imaging reagents technology segment comprises nanoparticles, fluorescent proteins, radiopharmaceuticals, quantum dots, fluorescent dyes and probes. The radiopharmaceuticals technology market of the medical imaging reagents accounted for the largest market due to the increased awareness about radioisotopes and high patient preference. Nevertheless, among these imaging reagent technologies, nanoparticles technology is anticipated to grow at the fastest growth rate of 9.1% from 2013 to 2019. Furthermore, medical imaging reagents application segment consists of diagnostics, drug discovery and development as well as research and development.


Among the various application areas medical imaging reagents, drug discovery and development is expected to witness the fastest growth during the forecast period owing to the growing adoption rate of medical imaging reagents in the development of nuclear medicines and medical interventions. However, diagnostics applications accounted for the largest market in terms of revenue due to the escalating patient base of cancer and cardiovascular diseases. It is expected that by the year 2019, the market value of imaging reagents for diagnostic purposes shall be worth more than USD 10 billion.


Geographically North America accounted for the largest market in the year 2012 (over 40%) followed by Europe. However, Asia Pacific is estimated to demonstrate the fastest growth rate owing to the expected rise in chronic diseases such as cancer and cardiovascular diseases coupled with rise in disposable income and growing awareness.

This market is highly consolidated in nature characterized by top five players occupying approximately 80% of the overall market share. The major players of this market include Bayer Healthcare AG, Becton Dickinson & Company, Bracco Imaging SpA, GE Healthcare, Lantheus Medical Imaging, Inc., Mallinckrodt Pharmaceuticals and Thermo Fisher Scientific, Inc.

The global medical imaging reagents market is segmented as follows:

Medical Imaging Reagents Market, by Class
Contrast Reagents
Optical Reagents
Nuclear Reagents

Medical Imaging Reagents Market, by Technology
Nanoparticles
Fluorescent proteins
Fluorescent dyes and probes
Radiopharmaceuticals
Quantum dots

Medical Imaging Reagents Market, by Applications
Diagnostics
Drug Discovery and Development
Research and Development

Medical Imaging Reagents Market, by Geography
North America
Europe
Asia-Pacific
Rest of the World (RoW)


About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Ms. Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Thursday 21 August 2014

Pain Management Therapeutics Market Analysis - 2018


The global pain management therapeutics market was valued at USD 40.93 billion and is expected to decline at a CAGR of (5.5%) from 2012 to 2018, to reach an estimated value of USD 29.47 billion in 2018.

Browse the full report at Pain Management Therapeutics Market http://www.transparencymarketresearch.com/pain-management-therapeutics.html

The global pain management therapeutics market is expected to experience a decline in revenues at a CAGR of (5.5%) during the forecast period, mainly due to patent expirations of the leading branded drugs. Although the global incidence rates of cancer, diabetes and other debilitating diseases that cause various chronic pain conditions is on a rise, the decline in market revenue is inevitable due to generic incursion for the top pain management drugs. Moreover, lack of a strong pipeline of novel or combination drugs that could help restore the positive growth of the overall market is also expected to contribute to the overall decline in the global pain management therapeutics market.

Administration of analgesics is the first line of treatment for the management of acute as well as chronic pain conditions. Some of the factors driving the growth of this market include the favorable regulatory and healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010. Also, the economic and effective nature of treatment with therapeutics compared to other modes, such as neurostimulation devices and acupuncture, will continue to fuel the uptake of drugs in pain management.


The market for non-steroidal anti-inflammatory drugs (NSAIDs) accounted for the largest share by revenue in 2011, of the total pain management therapeutics market by therapeutic class. This class comprises of some of the oldest known painkillers such as diclofenac, ibuprofen and Aspirin (acetylsalicylic acid) which are now commonly available as over-the-counter (OTC) medications, globally. However, the patent expiry of Celebrex (celecoxib) in 2013 is expected to negatively impact the market with a decline in revenues post patent expiry. The class of other non-narcotic analgesics consists of acetaminophen, sold as OTC drugs in the names of Tylenol, Panadol and Excedrin, and is expected to record the highest CAGR of 3.1% during the forecast period. Increase in the uptake of OTC drugs across the globe to overcome common pain conditions such as headache and body ache, will be responsible for this growth. The loss of patent exclusivity of other key brands such as Cymbalta (duloxetine), OxyContin (oxycodone) and Lidoderm (lidocaine) scheduled in the year 2013 will have a profound impact on the growth of the overall market.

North America was the largest regional market by revenue in 2011, due to the presence of one or more branded drugs belonging to each therapeutic class. However, the region is expected to record the lowest CAGR due to the looming patent expiries of these brands.

The market for generic formulations accounted for a larger share of the overall pain management therapeutics market in 2011, as against branded formulations. The market for branded pharmaceuticals was highly fragmented in 2011, with Pfizer, Inc., Purdue Pharma LP and Eli Lilly & Co. contributing to over 80% of the total market revenue. Other important players in this market include Endo Health Solutions, AstraZeneca PLC, Johnson & Johnson, and Merck & Co., Inc.


Pain Management Therapeutics Market, by Therapeutic Class
Anticonvulsants
Antidepressants
Anesthetics
NSAIDs
Opioids
Other Non-Narcotic Analgesics (Acetaminophen)
Anti-Migraine Agents


Pain Management Therapeutics Market, by Indication
Neuropathic Pain
Fibromyalgia
Arthritic Pain, by Type
Osteoarthritis
Rheumatoid Arthritis
Chronic Back Pain
Migraine
Post-operative Pain
Cancer Pain

Pain Management Therapeutics Market, by Geography
North America
Europe
Asia-Pacific
Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html


About Us
TransparencyMarket Researchis a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

U.S. Vaccine Market is Expected to Reach USD 17.4 Billion by 2018: Transparency Market Research


The U.S. vaccine market is estimated to be worth USD 12.8 billion in 2012 and is further expected to reach USD 17.4 billion by 2018, growing at a CAGR of 5.3% from 2012 to 2018. Human vaccine segment occupies about 80% of the U.S. vaccine market.

Browse the database at U.S. Vaccine Market - Industry Analysis, Size, Share, Growth, And Forecast 2012 – 2018 http://www.transparencymarketresearch.com/us-vaccine-market.html

U.S. will continue to lead the global vaccine market due to rising prevalence of infectious diseases in humans and animals, and advancement in biotechnology in the region. Short functional shelf life of certain vaccines will have negative impact on the market growth, but huge product pipeline of the multinational firms will overcome this concern and will drive the future growth of the market.

Pediatric vaccine segment in the U.S. human vaccine market enjoys high share as well as high growth rate due to government compulsion for child immunization. Adult & adolescent vaccine market is expected to grow moderately over the next six years due to rising awareness and increasing vaccination for human papillomavirus (HPV) and such other viral diseases.

Livestock vaccine is the leading segment of the overall U.S. animal vaccine market accounting for 58.1% in 2012 due to more organized dairy sector and increased awareness towards prevention of infectious diseases in cattle. Bovine vaccine market is the largest revenue generating segment of the overall Livestock vaccine market in 2012 due to rising vaccination to protect breeding animals against infectious diseases. Together feline vaccine and canine vaccine accounted for about 95.1% of the overall U.S. companion animal vaccine market in 2011.


In 2011, overall leading producers of human vaccine for the U.S. market were Sanofi-Aventis, Merck, GlaxoSmithKline, Pfizer, Sanofi-Pasture and Novartis. The leading producers of animal vaccine for the U.S. market includes Pfizer Animal Health, Merial (Sanofi-Aventis), Intervet/Schering-Plough (Merck) and Novartis Animal Health.

This report helps to identify factors, which will be the driving force behind the U.S. Vaccine market and sub-markets in the next six years. The report provides extensive analysis of the U.S. vaccine market, current market trends, industry drivers and challenges for better understanding of the U.S. vaccine market structure. The report has segregated the U.S. vaccine industry in terms of its product type. Annual estimates and forecasts are provided for the period 2012 through 2018 in terms of value in USD million.

Segments Analyzed


U.S. vaccine market- by Product
Human vaccine
Pediatric Vaccines
Adult & Adolescent vaccine
Other human vaccine


Animal vaccine
Livestock vaccine
Bovine vaccine
Porcine vaccine
Ovine vaccine

Companion animal vaccine
Feline vaccine
Canine vaccine
Equine vaccine
Other animal vaccine

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Nutraceutical Ingredients Market is Expected to Reach USD 29.5 Billion Globally in 2017


Global nutraceutical ingredients market is expected to be worth USD 20.8 billion in 2012 and is further expected to reach USD 29.5 billion in 2017, growing at a CAGR of 7.3% from 2012 to 2017. The body building segment is expected to be the largest segment at USD 9.5 billion in 2012. In the overall global market, Asia Pacific region is expected to maintain its lead position in terms of revenue till 2017. Asia Pacific is expected to enjoy 37.5% of global nutraceutical ingredients market revenue share in 2017 followed by North America.

Browse the detailed TOC at Nutraceutical Ingredients Market http://www.transparencymarketresearch.com/nutraceutical-ingredients-market.html

Increasing number of clinical studies confirming the health benefits of nutraceuticals and their broad applications in food, beverages, dietary supplements, and pediatric and adult nutritional preparations has provided support for the growing use of nutraceutical ingredients. Moreover, faster growth in consumption of nutraceutical ingredients worldwide, especially in developing economies has boosted the growth of nutraceutical ingredient market. In addition, increasing economic prosperity in developing countries including India, China, Brazil, Mexico, Russia,South Africa, South Koreaand Poland will enable consumers to spend more on health and nutrition. This will boost the future growth of the nutraceutical ingredient market.

Major segments of nutraceutical ingredients market include Body building, weight control, diabetes control and pain relief. In 2011, body building was the largest segment followed by weight control. The controlling diabetes segment was the third largest segment, accounting for 16.5% revenue share in 2011.

Amino acids and soy-based ingredients segments of body building market witnessed healthy growth rate during the review period (from 2007 to 2011). The growth in amino acid & soy-based ingredient segment is largely attributed to increased trend of fitness in most of the developing nations. The protein and peptide segment is also expected to have steady growth rate because of growing demand for nutritional diet and proper physic all over the world.


Nutraceutical ingredients presents opportunity for new entrants as well for existing players, due to the fact that most of the raw materials are abundant and product manufacturers are increasingly focusing on contract manufacturing outsourcing (CMO). Moreover, large product manufacturers are looking for backward integration, which will grow the competition into the market and will intern increase the market size of the nutraceutical ingredients.

This report is an effort to identify factors, which will be the driving force behind the nutraceutical ingredient market and its sub-markets over the next six years. The report provides extensive analysis of the nutraceutical industry, current market trends for better understanding of the nutraceutical ingredient market. The study presents a comprehensive assessment of the global nutraceutical ingredient market on the basis of:


Body Building
Probiotics and Prebiotics
Proteins
Peptides
Amino acids
Soy-based ingredients
Omega 3


Weight Control
Fibers and carbohydrates
Minerals
Vitamins & premixes

Controlling Diabetes
Antioxidants & Carotenoids
Dairy-based Ingredients

Pain Relief
Nutritional lipids and oils
Phytochemicals & Plant extracts

Geography
North America
Western Europe
Asia Pacific
Latin America
Eastern Europe
Middle East and Africa (MEA)

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Blog: http://www.tmrblog.com/